NMI 900 companion diagnostic - Medical Prognosis Institute
Latest Information Update: 20 Jan 2016
At a glance
- Originator Medical Prognosis Institute
- Developer Medical Prognosis Institute; Nemucore Medical Innovations
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ovarian cancer